22-25 June 2021 9th AIS (Antibody Industrial Symposium): T2EVOLVE will have 2 speakers: from T2 Evolve consortium will be honored to present their work and T2 evolve tasks/ objectives
- Adoptive cell therapy session: latest advancements – Sonia Guedan
- Enhancing Immunotherapy session: efficacy and safety : new preclinical models – Monica Casucci
15 April 2021, 3-5 pm 1st T2EVOLVE Multistakeholder Meeting: The purpose of this meeting is to engage external stakeholders early in the project, to help shape a T2EVOLVE stakeholder community, and foster opportunities for additional collaborations which augment the vision of the T2EVOLVE consortium.
The T2EVOLVE project had its first public appearance at the EHA-EBMT 3rd European CAR T-cell Meeting, with a workshop on February 5, from 7:00 PM CET entitled ‘How to rapidly move new CAR-Ts forward from bench to bedside? Key questions and answers!’
PRESS RELEASE: T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
T2EVOLVE is a breakthrough alliance of academic and industry leaders in cancer immunotherapy which started in January 2021, under the European Union’s Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and to increase access of cancer patients to immunotherapy with reprogrammed immune cells. Reprogramming is accomplished by genetic engineering with a T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR).
Figure 1: A tumor cell (left: cell nucleus stained blue, cell surface stained green) is tackled by a reprogrammed immune cell (right: synthetic chimeric antigen receptor -CAR- stained yellow). © Universitätsklinikum Würzburg.